Recordati Partners Well
Executive SummaryThese days, Italy is a tough country for drug makers to have as a home base, because the government imposes some of the strictest price controls in the world. Even highly innovative products are priced 30-40% lower than they are in other countries. Recordati, like other native Italian firms, has responded to the strictures by extending its marketing reach into other countries.
You may also be interested in...
The US Senate’s vote to approve legislation underpinning the US-Mexico-Canada trade agreement has been welcomed by the country’s off-patent industry.
By merging to create Viatris, Mylan and Pfizer’s Upjohn unit intend to occupy a space between generics players and big pharma by offering a broad array of affordable products all around the world.
Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.